Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial - Hegewisch-Becker, S; Graeven, U; Lerchenmüller, CA (Lancet Oncol, 2015)
et al.